Format

Send to

Choose Destination
Methods. 2005 May;36(1):3-10.

Immunogenicity of engineered antibodies.

Author information

1
Singapore Health Services, Singapore General Hospital, Singapore.

Abstract

Administration of a therapeutic antibody can lead to an anti-antibody response (AAR). Much effort has been applied to engineering antibodies with as little as possible non-human structure to minimize such responses. Here, we review reported AAR to murine, mouse-human chimeric, and humanized antibodies. Replacement of mouse immunoglobulin constant regions with human ones effects the largest immunogenicity reduction. Humanization of variable domains effects a further decrease.

PMID:
15848070
DOI:
10.1016/j.ymeth.2005.01.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center